SK286357B6 - Farmaceutický prostriedok s predĺženým uvoľňovaním a jeho použitie - Google Patents

Farmaceutický prostriedok s predĺženým uvoľňovaním a jeho použitie Download PDF

Info

Publication number
SK286357B6
SK286357B6 SK642-2001A SK6422001A SK286357B6 SK 286357 B6 SK286357 B6 SK 286357B6 SK 6422001 A SK6422001 A SK 6422001A SK 286357 B6 SK286357 B6 SK 286357B6
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
compound
plasma concentration
release pharmaceutical
sustained release
Prior art date
Application number
SK642-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK6422001A3 (en
Inventor
Lisa Benincosa
William Jusko
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286357(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of SK6422001A3 publication Critical patent/SK6422001A3/sk
Publication of SK286357B6 publication Critical patent/SK286357B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK642-2001A 1998-11-12 1999-11-12 Farmaceutický prostriedok s predĺženým uvoľňovaním a jeho použitie SK286357B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824893.3A GB9824893D0 (en) 1998-11-12 1998-11-12 Novel method of treatment
PCT/US1999/026746 WO2000027341A2 (en) 1998-11-12 1999-11-12 Novel method of treatment

Publications (2)

Publication Number Publication Date
SK6422001A3 SK6422001A3 (en) 2001-12-03
SK286357B6 true SK286357B6 (sk) 2008-08-05

Family

ID=10842389

Family Applications (1)

Application Number Title Priority Date Filing Date
SK642-2001A SK286357B6 (sk) 1998-11-12 1999-11-12 Farmaceutický prostriedok s predĺženým uvoľňovaním a jeho použitie

Country Status (40)

Country Link
EP (2) EP1759698A1 (el)
JP (1) JP2003521455A (el)
KR (2) KR20010080440A (el)
CN (3) CN101244062A (el)
AP (2) AP2005003432A0 (el)
AR (2) AR029149A1 (el)
AT (1) ATE366573T1 (el)
AU (1) AU768303B2 (el)
BG (2) BG65577B1 (el)
BR (1) BR9915284A (el)
CA (1) CA2350425C (el)
CO (1) CO5150158A1 (el)
CY (1) CY1106892T1 (el)
CZ (1) CZ299801B6 (el)
DE (1) DE69936533T2 (el)
DK (1) DK1135128T3 (el)
DZ (1) DZ2938A1 (el)
EA (2) EA009192B1 (el)
ES (1) ES2289833T3 (el)
GB (1) GB9824893D0 (el)
HK (1) HK1041202B (el)
HR (1) HRP20010344B1 (el)
HU (1) HUP0104262A3 (el)
IL (1) IL143088A0 (el)
MA (1) MA26759A1 (el)
MY (1) MY128347A (el)
NO (1) NO328391B1 (el)
NZ (1) NZ527132A (el)
OA (1) OA12193A (el)
PE (1) PE20001239A1 (el)
PL (1) PL349421A1 (el)
PT (1) PT1135128E (el)
RS (1) RS50130B (el)
SK (1) SK286357B6 (el)
TR (1) TR200101348T2 (el)
TW (1) TWI234456B (el)
UA (1) UA79730C2 (el)
UY (2) UY25797A1 (el)
WO (1) WO2000027341A2 (el)
ZA (1) ZA200103793B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
US20050107450A1 (en) * 2001-12-21 2005-05-19 Brown Kathleen K. Dosing regimen for ppar-gamma activators
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469331A (ja) * 1990-07-10 1992-03-04 Asahi Chem Ind Co Ltd 徐放性エマルジョン製剤
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU2479492A (en) * 1991-08-26 1993-03-16 Upjohn Company, The Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
US5478853A (en) * 1992-10-12 1995-12-26 Adir Et Compagnie Thazolidinedione compounds
CA2115587A1 (en) * 1993-02-18 1994-08-19 Hayato Kihara Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
CN1103590C (zh) * 1993-09-15 2003-03-26 三共株式会社 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes

Also Published As

Publication number Publication date
NZ527132A (en) 2005-01-28
CN1354661A (zh) 2002-06-19
WO2000027341A2 (en) 2000-05-18
AP2005003432A0 (en) 2005-12-31
CO5150158A1 (es) 2002-04-29
EP1135128A4 (en) 2003-07-16
ATE366573T1 (de) 2007-08-15
AR029149A1 (es) 2003-06-18
EP1135128B1 (en) 2007-07-11
GB9824893D0 (en) 1999-01-06
PE20001239A1 (es) 2000-12-24
SK6422001A3 (en) 2001-12-03
MY128347A (en) 2007-01-31
CA2350425A1 (en) 2000-05-18
DE69936533D1 (de) 2007-08-23
TWI234456B (en) 2005-06-21
BG110061A (bg) 2008-12-30
HK1041202A1 (en) 2002-07-05
ES2289833T3 (es) 2008-02-01
RS50130B (sr) 2009-03-25
HK1041202B (zh) 2007-10-05
BG105569A (en) 2002-01-31
EA200700968A1 (ru) 2008-06-30
OA12193A (en) 2006-05-09
CA2350425C (en) 2009-06-02
AP1580A (en) 2006-02-24
DE69936533T2 (de) 2008-03-13
EA200100539A1 (ru) 2001-12-24
AR029317A1 (es) 2003-06-25
KR20070048279A (ko) 2007-05-08
AU1719600A (en) 2000-05-29
UA79730C2 (en) 2007-07-25
IL143088A0 (en) 2002-11-10
EA009192B1 (ru) 2007-12-28
WO2000027341A3 (en) 2000-09-08
CN1771943A (zh) 2006-05-17
EP1759698A1 (en) 2007-03-07
PT1135128E (pt) 2007-10-12
JP2003521455A (ja) 2003-07-15
HRP20010344B1 (en) 2008-02-29
UY25801A1 (es) 2000-08-21
NO20012301L (no) 2001-07-09
CZ20011656A3 (cs) 2002-06-12
NO328391B1 (no) 2010-02-08
EP1135128A2 (en) 2001-09-26
MA26759A1 (fr) 2004-12-20
TR200101348T2 (tr) 2002-02-21
UY25797A1 (es) 2000-12-29
DZ2938A1 (fr) 2004-03-15
CY1106892T1 (el) 2012-01-25
BR9915284A (pt) 2002-02-13
CN1235586C (zh) 2006-01-11
CN101244062A (zh) 2008-08-20
HRP20010344A2 (en) 2002-06-30
YU37401A (sh) 2005-07-19
ZA200103793B (en) 2002-06-05
HUP0104262A3 (en) 2003-06-30
NO20012301D0 (no) 2001-05-10
BG65577B1 (bg) 2009-01-30
KR20010080440A (ko) 2001-08-22
HUP0104262A2 (en) 2002-08-28
AU768303B2 (en) 2003-12-04
CZ299801B6 (cs) 2008-11-26
PL349421A1 (en) 2002-07-29
DK1135128T3 (da) 2007-11-05

Similar Documents

Publication Publication Date Title
ES2312221T3 (es) Composicion farmaceutica para liberacion modificada de un sensibilizador de insulina y metformina.
KR100666591B1 (ko) 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
US20070275063A1 (en) Sustained release pharmaceutical compositions and methods of treatment using the same
JP2005247865A (ja) チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療
KR20010013843A (ko) 로지글리타존 및 인슐린을 사용한 당뇨병의 치료
SK286357B6 (sk) Farmaceutický prostriedok s predĺženým uvoľňovaním a jeho použitie
AU2007249132A1 (en) Novel method of treatment
AU2005200702A1 (en) Novel method of treatment
MXPA01004853A (en) Novel method of treatment
KR20010024481A (ko) 고혈당증 치료용 티아졸리딘디온의 용도
MXPA00003633A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
MXPA00000631A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20111112